Cancer drugs

This article covers cancer drugs from a pathology perspective.

Drugs in a table

Non-proprietary name	Trade name	Cost	Indication	Notes
cetuximab	Erbitux	5267 Euros/month^[1]	stomach cancer, head & neck cancer	notes?
trastuzumab	Herceptin	3345 Euros/month^[1]	breast cancer, stomach cancer	notes?
gefitinib	Iressa	3496 Euros/month^[1]	lung cancer	EGFR inhibitor - like erlotinib
panitumumab	Vectibix	3537 Euros/month^[1]	indication ???	notes?
fulvestrant	Faslodex	719 Euros/month^[1]	breast cancer	selective estrogen receptor down-regulator (SERD)
letrozole	Femara	4189 Euros/month^[1]	indication ???	non-steroidal aromatase inhibitor
imatinib	Gleevec/Glivec	4189 Euros/month^[1]	ALL, CML	tyrosine kinase inhibitor
dasatinib	Sprycel	7513 Euros/month^[1]	ALL, CML	tyrosine kinase inhibitor
nilotinib	Tasigna	5685 Euros/month^[1]	CML	tyrosine kinase inhibitor
lapatinib	Tyverb	3441 Euros/month^[1]	breast cancer	tyrosine kinase inhibitor / HER2 growth receptor pathway blockade

↑ ^1.00 ^1.01 ^1.02 ^1.03 ^1.04 ^1.05 ^1.06 ^1.07 ^1.08 ^1.09 Grill, Markus; Hackenbroch, Veronika (2011), "[Medizin: Das grosse Versprechen]", Der Spiegel (32): 124-128, 8.8.2011